Guest guest Posted December 29, 2005 Report Share Posted December 29, 2005 Vol. No: 30:02 Posted: 2/22/05 The Skinny on Gastric Bypass What Pharmacists Need to Know A. Fussy, PharmD Candidate, BS Pharm Sci, minor Nutrition Sci, North Dakota State University Status: post Lap Roux-En-Y 6/03/03 US Pharm. 2005;2:HS-3-HS-12. The ever-increasing obesity ep idemic in the United States has been well established in current medical literature. Some statistics report that as many as two thirds1 of U.S. citizens are overweight, and as many as half of those individuals, roughly 50 million,2 are classified as being obese (having a body mass index [bMI] of 30 or more).1 Unfortunately, those who are considered morbidly obese are the largest growing subgroup of obese individuals—encompassing nearly 12 million people.1,2 Morbid obesity is defined as having a BMI of greater than or equal to 40 and being at least 100 pounds above ideal body weight standards.3 It has been well documented that morbid obesity is associated with numerous health-related comorbidities,1-8 as listed in TABLE 1. The evolution of laparoscopic (minimally invasive) surgical techniques that have improved surgical outcomes, coupled with an increasing willingness among third-party payers to cover bariatric procedures (in hopes of counteracting the enormous costs of obesity- related comorbidities), has led to a dramatic increase in the number of patients seeking surgical intervention.9,10 In fact, Medicare announced in July 2004 that it is shunning fad diets and instead focusing on considering paying for obesity surgery in order to provide a permanent and effective means of weight loss.10 THE ROLE OF PHARMACISTS According to the American Society for Bariatric Surgery, over 110,000 patients were projected to undergo bariatric (weight loss) surgery in 2004.9 That number was up from the 25,000 surgeries performed in 1998.10 The increasing popularity of gastric bypass surgery leads to a new gamut of health care concerns that are relevant to the practice of pharmacy, both in the inpatient and outpatient settings. Pharmacists will need to acquire an acceptable knowledge base on the malabsorptive and nutritional deficiency characteristics associated with these particular patients in order to provide appropriate pharmaceutical care, adequate patient monitoring, medically sound supplementation recommendations, and patient counseling. In doing so, there are several parameters for pharmacists to consider, including the different types of weight loss surgeries performed, how they work to induce weight loss, the health complications and risks that result, and patient monitoring parameters that are important to ensure a patient's health. Pharmacists will play an important role in the postsurgical management of electrolytes, pain management, parenteral nutrition, prophylactic use of anticoagulants and antibiotics to prevent clot formation, and life-long medication and nutritional supplementation monitoring for appropriateness of therapy in bariatric patients.11,12 TYPES OF BARIATRIC SURGERIES The term " gastric bypass " is often misused as a sort of blanket term, meant to encompass all forms of bariatric surgery. However, the surgeries differ extensively in the nature of their anatomical restrictive and malabsorptive capacities. These differences incurred from bariatric surgery lead to varying changes in digestion and absorption, which are important parameters affecting the extent of weight loss, the potential for nutritional deficiencies, and the possibility of pharmacokinetic and bioavailability variations in drug absorption.2-8 Purely Restrictive Procedures The most common bariatric procedures performed in the U.S. today can be divided into two basic categories: purely restrictive procedures and combination procedures that are malabsorptive and restrictive in nature.1,4,12 Purely restrictive surgeries include vertical banded gastroplasty (VBG) and adjustable gastric banding (AGB), often called the Lap-Band surgery. They involve the formation of a small pouch at the top of the stomach that restricts the volume of food a patient is able to consume. Food is then allowed to pass normally (albeit more slowly) through the rest of the digestive system.12 Weight loss is not nearly as drastic with these restrictive surgeries, and they are less commonly performed in general. As these surgeries do not involve intestinal bypass, nutrient deficiencies are far less common in these procedures and malabsorption/bioavailability concerns do not exist (see FIGURES 1 AND 2).2-8 Combination Procedures The combination procedures include the Roux-En-Y (pronounced roo-en- y) gastric bypass (RYGB) and biliopancreatic diversion (BPD) with or without a duodenal switch (DS) (see FIGURES 3, 4, and 5).1,12 BPD involves extensive resectioning of the small bowel and removal of two thirds of the lower portion of the stomach. In this procedure absorption is limited to a brief portion of the end (ileum) of the small intestine, which results in extensive malabsorption of nutrients. Although weight loss is extensive with this surgery, significant complications, malnutrition, and inconvenient frequent foul-smelling stools can occur. For this reason, BPD is largely reserved for the superobese (BMI of 50 or higher).2,4,7,12 The other combination procedure, RYBG, is considered the gold standard in bariatric procedures. It is the most commonly performed, longest and most extensively studied bariatric procedure to date, and is the most effective procedure (endorsed by the National Institutes of Health) in terms of producing long-lasting, successful weight loss.2-8 For this reason, the remainder of this article will focus on the nutritional and malabsorptive concerns associated with just this procedure (although still applicable to BPD/DS), as it is the most common procedure that pharmacists are likely to encounter. The RYGB surgery involves formation of a small 1-ounce pouch at the junction of the esophagus and the very top of the stomach (the cardia). This portion of the stomach is resistant to stretching, which helps keep the pouch small over time and greatly limits the amount of food that the patient can consume. The pouch is created by stapling off a small thumb-sized portion from the rest of the stomach, which may or may not then be permanently separated. The small pouch merely functions as a reservoir for food and does not produce stomach acid. The remaining separated stomach continues to produce stomach acid and gastric juices but will never again receive food. The small intestine is then cut about 18 inches downstream from the lower stomach base. The free piece of bowel (called the Roux limb) is then reattached upwards to the small pouch at a stomal (outlet) site. This connection is purposefully shaped into a narrow outlet roughly the size of a pencil eraser, in order to restrict the rate that food passes out of the pouch. This keeps the patient fuller for a longer period of time and is the restrictive portion of the procedure. 2,4-8,12,13 The 18-inch small bowel portion " hanging " off the end of the lower separated stomach is then attached to the Roux limb at a certain distance (50150 cm) from the stomal connection, in a Y-shaped formation. This allows for a small amount of gastric juice still produced in the bottom stomach to be introduced to passing food to aid in digestion. This is the portion of the surgery that creates malabsorption of calories, by bypassing the duodenum and early jejunum (as well as the entire lower stomach) where the majority of absorption occurs.2,4-8,12,13 POST ROUX-EN-Y GASTRIC BYPASS Immediately post-op the patient is required to adhere to a liquid diet for roughly a month, followed by a progressively more solid diet until a normal diet is resumed about six to eight weeks post-op (depending on the surgeon's requirements). At any given sitting, patients are able to consume only one quarter to three quarters of a cup of food, depending upon its consistency, resulting in a large reduction in caloric intake.12-14 This reduction in intake, coupled with the malabsorption, results in dramatic weight loss. It is estimated that 95% of patients will lose an average of 7075% of their excess weight within two years of surgery, and at five years post-op, up to 85% of patients will maintain a minimum of 50% of their excess weight loss.9 (It is important to note that due to this massive weight loss in such a short period, patients may be at an increased risk of gallstone formation. Some surgeons will opt to circumvent this risk by removing the gallbladder at the time of surgery, or they may also opt for a more conservative approach of prescribing a gallstone dissolution agent such as ursodiol for the first three to six months post-op, when the most rapid weight loss occurs.)11 In addition to massive weight loss, nearly all comorbidities associated with the obesity are completely reversed or substantially improved following the surgery.1,4,15 In fact, almost 80% of patients experience complete resolution of their type 2 diabetes within days of surgery,12 and other comorbidities such as GERD, hypertension, and sleep apnea also disappear along with the weight.1,4,12,15 However, the surgery is not without risks, and the features that allow for the tremendous weight loss are the same culprits that induce malabsorption of certain drugs and vital nutrients, and an adverse reaction called dumping syndrome. DUMPING SYNDROME Dumping syndrome is caused by intake of highly concentrated substances that fill the lower small intestines too quickly before they are digested. This occurs when RYGB patients eat meals high in refined sugars or fat, even in small quantities. The concentrated highly osmolar substances travel the shortened distance to the lower intestine quickly, resulting in a fluid shift into the small intestine. This can result in cramping, tachycardia, diaphoresis, vomiting, or diarrhea in the early dumping phase. A later dumping phase can occur as a result of the efficiency of the small bowel in absorbing simple sugars. A small amount of simple sugars may cause a rapid glucose spike in the blood, triggering insulin release. The small amount of sugar ingested is not large enough in comparison to the amount of insulin that is released, and hypoglycemia may ensue. This causes the patient to feel extremely fatigued and sleepy. Unfortunately, the hypoglycemia may also stimulate hunger, causing a vicious cycle of overeating and potentially surgery failure. For this reason, most bariatricians recommend limiting the sugar content in foods to less than 16 g per serving (also known as " sweet 16 " ). Pharmacists can also instruct patients to consume a high-protein diet consisting of frequent small, dry meals (no fluids 30 minutes before or 12 hours after ingestion), with mi nimal refined carbohydrates or fats, in order to avoid dumping.7,8,12-16 NUTRIENT DEFICIENCIES Some of the most common nutrient deficiencies that occur in RYGB patients are calcium, folate, vitamin B12, and iron deficiencies, and protein malnourishment.16 Additional surgical complications are outlined in TABLES 2 AND 3.2,3,5-8,11,12,14 The nutrient deficiencies that occur are due to the fact that a large portion of the small intestine is bypassed following the surgery, in order to create malabsorption of calories for enhanced weight loss (consequently, vital nutrients are malabsorbed as well). The type and extent of nutritional deficiencies vary greatly, depending upon the length of small intestines bypassed, which is different for every patient. Individuals therefore will have varying supplementation needs, but all patients will require one to two daily multivitamins for the rest of their lives after surgery.2- 8,12,14,16 See TABLE 4 for supplementation needs for RYGB patients. Calcium Deficiency Calcium is predominantly absorbed into the body by the duodenum, which is bypassed in RYBG surgery. As a result, calcium deficiency can be a common occurrence in patients if appropriate life-long supplementation is not initiated. Additionally, the solubility and amount of elemental calcium provided vary greatly among the various calcium salts and thus should be considered when a product is recommended. This is particularly important in bypass patients who do not have stomach acid present in the new stomach pouch to aid in absorption. As a result, the absorption of less soluble calcium salts (calcium carbonate) that require stomach acid for absorption is lower, and the absorption of more soluble calcium salts (calcium citrate) that do not require stomach acid for absorption is higher. RYGB patients are also more susceptible to lactose intolerance, as the lactase enzyme that breaks down milk sugars is secreted at the distal bypassed portion of the stomach. This may result in decreased intake of dairy products, further worsening deficiency.7,12,16-30 Of particular concern regarding calcium supplementation is the number of providers who still recommend calcium carbonatecontaining products to RYGB patients, even in the face of the achlorhydric environment that the new stomach pouch creates. Calcium carbonate products are often recommended despite their relatively insoluble nature due to the larger degree of elemental calcium they provide in comparison to other salt forms (carbonate provides 40% elemental calcium, vs. citrate which provides 21%). To overcome the solubility issue, many providers advise that patients take their carbonate products with food to enhance absorption. It has been proposed that after food intake, the acid-producing parietal cells (located in the body of the stomach) become stimulated to produce more acid, thus improving absorption. This mechanism does not apply to RYGB patients, however, as the bottom portion of the stomach is entirely bypassed after surgery and the acid-secreting parietal cells will never again be stimulated by food intake. Absorption of carbonate- containing products will therefore not be enhanced by this means. This is the perfect reason for pharmacists to come into play and to recommend more soluble salt forms such as citrate or microcrystalline hydroxyapatite concentrate (MCHC), which are the most absorbable forms for RYGB patients.7,12,16-30 Vitamin B12 Deficiency Vitamin B12 deficiency can also occur after RYGB. Hydrochloric acid and pepsin released in the lower stomach are required to separate B12 from protein sources in food. After separation occurs, the B12 attaches to binder proteins present in saliva and gastric juice. Pancreatic enzymes from the upper small intestine are then secreted, which release the B12 from the binder proteins. The B12 then binds to intrinsic factor (produced in the lower portion of the stomach) in the duodenum and is transported to the distal ileum of the small intestine, where it is absorbed in the presence of calcium.5,7,12,14,16,31-34 Following RYGB where the lower portion of the stomach is removed or partitioned off, cells are lost that secrete both hydrochloric acid and intrinsic factor. Additionally, the pancreatic enzymes that release the B12 from binder proteins are lost as the upper portion of the small intestine is bypassed, and absorption that occurs in the distal ileum is also impaired, as this portion of the small intestine may be bypassed. To worsen matters, B12 absorption in the distal ileum is dependent upon the presence of calcium, which is another common deficiency after RYGB, and folic acid deficiency (which can also occur after RYGB) may impair B12 absorption as well. Pharmacists serve the important role of ensuring proper B12 prophylactic supplementation with sublingual or intranasal preparations that will be released directly into the bloodstream for absorption, thus avoiding the problematic loss of digestive juices and intrinsic factor. Parenteral monthly injections are also an option for patients, although usually reserved for diagnosed deficiency.5,7,12,14,16,31-34 Protein Malnourishment Protein malnourishment can be a common risk in the first 12 months following RYGB as well, as the amount of calories patients are able to consume is extremely diminished given the small pouch size. In addition, animal proteins may be more difficult for bypass patients to digest and absorb, as the bulk of digestion (following breakdown in the stomach) occurs in the small intestine. This occurs when pancreatic enzymes are released into the small intestines, which break the protein down into absorbable peptides and amino acids. Following the surgery, the 1-ounce pouch may have difficulty churning/digesting animal proteins adequately, given its small size, and when a portion of the small intestine is bypassed, the digestive process is also consequently reduced. Thus, it is important to ensure adequate protein intake from easily absorbable and complete (high quality) protein sources, such as whey or egg albumen/egg whites.5,7,12-15,35 Supplements such as whey are complete protein sources that provide all the essential amino acids needed in the diet and are easier for bypass patients to efficiently break down in the months immediately after surgery when their protein intake is the most impaired. The highest quality whey proteins on the market are whey protein isolate, ion exchange whey protein, whey hydrolysate, or whey peptides. These contain very high levels of branched chain amino acids (leucine, valine, isoleucine), which can prevent muscle catabolism or wasting that can occur with protein malnourishment. These supplements also have a high Net Protein Utilization (NPU), a high Protein Efficiency Ratio (PER), and a high Biological Value (BV), which indicate that they are utilized very efficiently by the body. The maximum amount of protein that can be absorbed by the average person per meal is 30 g, which most of these provide in one to two 4-ounce servings. All of these characteristics can be found by examining the supplement's product label.5,7,12-15,35 It is important to note that many RYGB patients may need protein supplementation for life to ensure proper intake, but after one year postsurgery some may be able to take in adequate amounts of protein through their diets (approximately 0.81 g of protein per kg body weight, or a minimum of 60 g daily), after their pouches are fully healed, and these liquid supplements will no longer be necessary. It is also important to remember to check the supplement label for sugar content, to ensure it contains less than 16 g of sugar per serving, in order to prevent dumping syndrome.5,7,12-15,35 Iron Deficiency The major site of absorption for iron is in the first part of the small intestine, the duodenum. This portion of the intestine is bypassed following RYGB, and thus iron deficiency (and possibly anemia) is a possible result. As a consequence of the surgery, food has a lack of contact time with gastric acid, which results in a reduced conversion of dietary iron from the insoluble ferric form to the more soluble ferrous form. The different iron salt formulations available for supplementation provide varying amounts of elemental iron, varying extents of absorption, and variable side effects. Ferrous sulfate is less effectively absorbed in RYGB patients as a result of the lack of stomach acid present that is required for absorption, and it has a higher degree of GI complaints than other salt forms. Polysaccharide iron, carbonyl iron, ferrous fumarate, and ferrous gluconate are more absorbable forms of iron for RYGB patients, and some studies suggest that taking vitamin C with the iron supplement will enhance absorption after surgery.5,7,12,13,16,32,33,36 PREVENTING MEDICATION MISADVENTURES Another important role that pharmacists have in providing care to bariatric patients is to monitor medication profiles for appropriateness of therapy. For example, metformin should be avoided in patients who have B12 deficiency, due to the drug's ability to cause the deficiency itself, and many bariatric surgeons recommend that NSAIDs be avoided permanently following bypass surgery,7,13,25 due to the enhanced risk of GI bleeding, given the small surface area of the new pouch. Enteric-coated preparations are also a concern as they may have altered absorption, given the extent of intestinal bypass. The solubility of all drugs in general must be considered, given the achlorhydric nature of the RYGB patient's new anatomy.25 There are also special considerations when administering total parenteral nutrition (TPN) to bariatric patients. Pharmacists should be on alert for refeeding syndrome in bariatric patients. Refeeding syndrome is a nutritional complication that can occur in obese patients experiencing massive weight loss during the post- operative period when they are severely malnourished. The syndrome is primarily associated with hypophosphatemia, as well as drops in serum potassium, magnesium, calcium, and less commonly, cardiac dysfunction and fluid retention as well. The mechanism of these electrolyte abnormalities is thought to be related to the acute administration of macronutrients (primarily dextrose) that promote anabolism (muscle building) in a state of overall depleted electrolyte body stores (due to post-operative malnourishment). Cardiac dysfunction is thought to be related to an acute volume expansion that increases cardiac demand. Lipid and dextrose concentratons for post-op bariatric patients should be dosed lower than the amount needed to maintain their current weight, while protein, on the other hand, should be dosed at 12 g per kg adjusted body weight in order to avoid muscle catabolism.12 Additionally, as pregnancy is not recommended in the first 18 months following the surgery, pharmacists have a role in ensuring that bypass patients are utilizing appropriate contraceptive methods. This is particularly important, as fertility may improve in obese patients who lose weight, and there have been case reports of malabsorption of oral contraceptives. This may require some patients to convert to other means of contraception (barrier methods, transdermal patches).6-8,13,37 Considering all of the above concerns and the growing number of bariatric surgeries being performed, the role of pharmacists as part of a multidisciplinary team to provide bariatric patients with appropriate medical care is vital and will continue to grow in the future. To comment on this article, contact editor@.... REFERENCES 1. Buchwald H, Avidor Y, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004;292(14):1724-1737. 2. Mac KG, Schauer PR, et al. Bariatric surgery: a review. Gen Surg News. April 2001;1-12. 3. American Society for Bariatric Surgery Online. Rationale for the surgical treatment of morbid obesity. Updated April 6, 1998. Accessed June 2003. www.asbs.org/html/rationale.html. 4. Cummings DE, Overduin J, -Schubert KE. Gastric bypass for obesity: mechanisms of weight loss and diabetes resolution. J Clin Endocrin Metab. 2004;89(6):2608-2615. 5. Deitel M, Shikora SA. The development of the surgical treatment of morbid obesity. J Am Coll Nutr. 2002;21(5):365-371. 6. Gastrointestinal surgery for severe obesity. Proceedings of a National Institutes of Health Consensus Development Conference. March 25-27, 1991, Bethesda, MD. Am J Clin Nutr. 1992;55(2 suppl):487s-619s. 7. B. Weight Loss Surgery. 2nd ed. Tarentum (PA): Word Association Publishers; 2002. 8. American Obesity Association Online. American Obesity Association Fact Sheets. Accessed September 2004. www.obesity.org. 9. Courcoulas AP. The evolution of surgery for obesity: past, present, & future. WLS Lifestyles. Spring 2004;1(1):20-21. 10. MSNBC News Online. Medicare backs gastric bypass for weight loss. Updated July 20, 2004. Accessed July 21, 2004. www.msnbc.com/id/5469347. Associated Press. 11. Garza SF. Bariatric weight loss surgery: patient education, preparation, and follow-up. Crit Care Nurs Quart. 2003;26(2):101- 104. 12. Elliot K. Nutritional considerations after bariatric surgery. Crit Care Nurs Quart. 2003;26(2):133-138. 13. ton Northwestern Healthcare Bariatric Services. Living with your gastric bypass surgery. June 2004. 14. Rezabek K. Rush Presbyterian Nutrition and Wellness Center Gastric Bypass Diet. Patient guide. June 2003. 15. Dixon JB, O'Brien PE. Health outcomes of severely obese type 2 diabetic subjects one year after laparoscopic adjustable gastric banding. Diabetes Care. 2002;25(2):358-363. 16. Kushner R. Managing the obese patient after bariatric surgery: a case report of severe malnutrition and review of the literature. J Parenteral Enteral Nutr. 2000;24:126-132. 17. ton Northwestern Healthcare Bariatric Services. Long-term vitamin supplementation. June 2004. 18. Chang CG, Simms T, et al. A comparison of the absorption of calcium citrate and calcium carbonate following Roux-En-Y gastric bypass. Paper presented at 21st Annual ASBS Meeting, June 12-18, 2004. Abstract. 19. Sakhaee K, Bhuket T, -Huet B, et al. Meta-analysis of calcium bioavailability: a comparison of calcium citrate with calcium carbonate. Am J Ther. 1999;6(6):313-321. 20. Recker RR. Calcium absorption and achlorhydria. N Engl J Med. 1985;313(2):70-73. 21. Nicar MJ, Pak CY. Calcium bioavailability from calcium carbonate and calcium citrate. J Clin Endocrinol Metab. 1985;61(2):391-393. 22. Heller HJ, A, Haynes S, et al. Pharmacokinetics of calcium absorption from two commercial calcium supplements. J Clin Pharmacol. 1999;39:1151-1154. 23. Harvey JA, Zobitz MM, Pak CY. Dose dependency of calcium absorption: a comparison of calcium carbonate and calcium citrate. J Bone Mineral Research. 1988;3(3):253-258. 24. Faloon W. Calcium: keep what you take. Life Extension Magazine Online. Written March 1999. Accessed July 2004. www.lef.org/lefcms. 25. Wolinsky I, L, eds. Nutrition in Pharmacy Practice. Washington: American Pharmaceutical Association; 2002:22-54. 26. National Nutritional Foods Association (NNFA) Online. NNFA scientific backgrounder on calcium forms: information for bariatric surgery physicians and patients. Accessed July 2004. www.nnfa.org/services/science/bg_calcium.html. 27. Brody T. Nutritional Biochemistry. 2nd ed. San Diego: Academic Press; 1999. 28. Groff JL, et al. Advanced Nutrition and Human Metabolism. 2nd ed. St : West Publishing; 1995:353-366. 29. Gonnelli S, Cepollaro C, Camporeale A, et al. Acute biochemical variations induced by two different calcium salts in healthy perimenopausal women. Calcif Tissue Int. 1995;57:175-177. 30. Levenson DI, Bockman RS. A review of calcium preparations. Nut Rev. 1994;52(7):221-232. 31. Brolin RE, Gorman JH, Gorman RC, et al. Are vitamin B12 and folate deficiency clinically important after Roux-En-Y gastric bypass? J Gastrointest Surg. 1998;2:436-442. 32. Brolin RE, Gorman RC, Milgrim LM, et al. Multivitamin prophylaxis in prevention of post-gastric bypass vitamin and mineral deficiencies. Int J Obesity. 1991;15:661-667. 33. Behrns KE, CD, Sarr MG. Prospective evaluation of gastric acid secretion and cobalamin absorption following gastric bypass for clinically severe obesity. Dig Dis Sci. 1994;39(2):315-320. 34. CD, Herkes SB, Behrns KE, et al. Gastric acid secretion and vitamin B12 absorption after vertical Roux-En-Y gastric bypass for morbid obesity. Ann Surg. 1993;218(1):91-96. 35. Sepe RJ. Protein: best friend of the bariatric patient. WLS Lifestyles. Summer 2003;1(1):32-33. 36. Rhode BM, Shustik C, Christou N, et al. Iron absorption and therapy after gastric bypass. Obesity Surg. 1999;9:17-21. 37. NIDDK Weight-Control Information Network Online. Gastrointestinal Surgery for Severe Obesity. Accessed October 2004. www.niddk.nih.gov/publications/gastric.htm. Vol. No: 30:02 Posted: 2/22/05 Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.